Clinical Trial Update: Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment [NA]

View source ↗

Summary

A clinical study is evaluating the safety and effectiveness of BCMA-GPRC5D CAR-T in relapsed/refractory multiple myeloma after third-line or higher therapy, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA-GPRC5D CAR-T

Snippet

Sponsor: Guangzhou Bio-gene Technology Co., Ltd | Conditions: Relapsed/Refractory Multiple Myeloma | NA | Status: NOT_YET_RECRUITING